Pharmos
Corporation to Present at the BIO CEO & Investor Conference
Iselin
NJ, February 26, 2003 - Pharmos Corporation (Nasdaq:
PARS and Nasdaq Europe: PHRM) announced today Robert W.
Cook, Executive Vice President & CFO, will present
an overview of the Company to members of the financial
community, the healthcare industry and the media at the
BIO CEO & Investor Conference on Thursday, February
27, at 12:00 noon Eastern Time at the Waldorf-Astoria
in New York. Pharmos' presentation will concentrate on
dexanabinol, the Company's lead compound under development,
currently being tested clinically for traumatic brain
injury (Phase III trial) and mild cognitive impairment
in cardiac surgery patients (Phase IIa). The presentation
will also outline some of the promising earlier stage
compounds from the Company's rich neurological pipeline.
A
simultaneous webcast of Pharmos' presentation will be
available at http://www.firstcallevents.com/service/ajwz374781433gf12.html,
and will be archived for a limited time after the conference.
Pharmos
discovers, develops, and commercializes novel therapeutics
to treat a range of indications, in particular neurological
and inflammation-based disorders. The Company's first
neuroprotective product is dexanabinol, a synthetic tricyclic
non-psychotropic dextrocannabinoid, currently undergoing
clinical testing as a treatment for TBI and as a preventive
agent against post-surgical cognitive impairment. Other
dextrocannabinoid compounds and CB2 receptor agonist compounds
from Pharmos' proprietary synthetic cannabinoid library
are being studied in pre-clinical programs targeting stroke,
pain, multiple sclerosis and other disorders.
Statements
made in this press release related to future beneficial
expectations and projections of the Company are forward-looking
and are made pursuant to the safe harbor provisions of
the Securities Litigation Reform Act of 1995. Such statements
involve risks and uncertainties which may cause results
to differ materially from those set forth in these statements.
Additional economic, competitive, governmental, technological,
marketing and other factors identified in Pharmos' filings
with the Securities and Exchange Commission could affect
such results.
back
to News Room
